Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome

被引:5
作者
Ji, Ying [1 ]
Wang, Yan-Li [2 ]
Xu, Fang [1 ]
Jia, Xi-Bei [1 ]
Mu, Su-Hong [1 ]
Lyu, Hui-Yan [1 ]
Yuan, Xue-Ying [1 ]
Na, Shi-Ping [1 ]
Bao, Yu-Shi [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 1, Dept Nephrol, 23 Youzheng St, Harbin 150001, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Rheumatol, Harbin, Peoples R China
关键词
podoplanin; C-type lectin-like receptor 2; nephrotic syndrome; hypercoagulable state; thrombosis; VENOUS THROMBOSIS; TUMOR-METASTASIS; RECEPTOR CLEC-2; THROMBOEMBOLISM; PLATELETS; INTEGRITY; ROLES; MICE;
D O I
10.1177/10760296221108967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = -0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Risk of Arterial Thromboembolism, Venous Thromboembolism, and Bleeding in Patients with Nephrotic Syndrome: A Population-Based Cohort Study
    Vestergaard, Soren Viborg
    Birn, Henrik
    Darvalics, Bianka
    Nitsch, Dorothea
    Sorensen, Henrik Toft
    Christiansen, Christian Fynbo
    AMERICAN JOURNAL OF MEDICINE, 2022, 135 (05) : 615 - +
  • [42] ELEVATED LEVELS OF TUMOR-NECROSIS-FACTOR-ALPHA IN THE NEPHROTIC SYNDROME IN HUMANS
    SURANYI, MG
    GUASCH, A
    HALL, BM
    MYERS, BD
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (03) : 251 - 259
  • [43] Podoplanin-positive dilated lymphatic vessels in duodenum associates with three-month mortality in patients with cirrhosis
    Juneja, Pinky
    Sharma, Aarti
    Shasthry, S. M.
    Kumar, Guresh
    Tripathi, Dinesh M.
    Rajan, V.
    Rastogi, Archana
    Sarin, Shiv K.
    Kaur, Savneet
    FRONTIERS IN PHYSIOLOGY, 2023, 14
  • [44] The role of platelet activation in determining response to therapy in patients with primary nephrotic syndrome
    Kocyigit, Ismail
    Yilmaz, Mahmut Ilker
    Simsek, Yasin
    Unal, Aydin
    Sipahioglu, Murat Hayri
    Eroglu, Eray
    Dede, Fatih
    Tokgoz, Bulent
    Oymak, Oktay
    Utas, Cengiz
    PLATELETS, 2013, 24 (06) : 474 - 479
  • [45] The Association of Syndecan-1, Hypercoagulable State and Thrombosis and in Patients With Nephrotic Syndrome
    Chen, Xin
    Geng, Xuemei
    Jin, Shi
    Xu, Jiarui
    Guo, Man
    Shen, Daoqi
    Ding, Xiaoqiang
    Liu, Hong
    Xu, Xialian
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [46] Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism
    Resh, Mohammad
    Mahmoodi, Bakhtawar K.
    Navis, Gerjan J.
    Veeger, Nic J. G. M.
    Lijfering, Willem M.
    THROMBOSIS RESEARCH, 2011, 127 (05) : 395 - 399
  • [47] Low T3 Syndrome in Adult Patients with Nephrotic Syndrome
    Tatar, Erhan
    Isikyakar, Tolgay
    Gungor, Ozkan
    Yeniay, Kezban Pinar
    Tasli, Funda
    Ok, Ebru Sevinc
    Sen, Sait
    Demirci, Meltem Sezis
    Basci, Ali
    TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, 2014, 23 (02): : 137 - 141
  • [48] The value of urinary soluble urokinase plasminogen activator receptor (suPAR) in children with nephrotic syndrome
    Phuong Anh Le Thy
    Kiem Hao Tran
    Thuy Yen Hoang Thi
    Minh Phuong Phan Thi
    Huu Son Nguyen
    AIMS MEDICAL SCIENCE, 2021, 8 (02): : 163 - 174
  • [49] Cryptococcosis in Patients with Nephrotic Syndrome: A Pooled Analysis of Cases
    Fang, Wenjie
    Hong, Nan
    Li, Yingfang
    Liu, Jia
    Zhang, Lei
    Jiang, Weiwei
    Qiu, Bo
    Xu, Jianping
    Liao, Wanqing
    Chen, Min
    Pan, Weihua
    MYCOPATHOLOGIA, 2017, 182 (5-6) : 517 - 525
  • [50] Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome
    Anne M. Schijvens
    Rob ter Heine
    Saskia N. de Wildt
    Michiel F. Schreuder
    Pediatric Nephrology, 2019, 34 : 389 - 403